Sarepta Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Sarepta Therapeutics has a total shareholder equity of $1.2B and total debt of $1.2B, which brings its debt-to-equity ratio to 100.5%. Its total assets and total liabilities are $3.6B and $2.4B respectively. Sarepta Therapeutics's EBIT is $81.0M making its interest coverage ratio -6.6. It has cash and short-term investments of $1.2B.
Key information
100.5%
Debt to equity ratio
US$1.23b
Debt
| Interest coverage ratio | -6.6x |
| Cash | US$1.20b |
| Equity | US$1.22b |
| Total liabilities | US$2.38b |
| Total assets | US$3.60b |
Recent financial health updates
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well
Jan 22
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Recent updates
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well
Jan 22Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Jan 16Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($2.7B) exceed its short term liabilities ($699.5M).
Long Term Liabilities: SRPT's short term assets ($2.7B) exceed its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: SRPT's net debt to equity ratio (2.4%) is considered satisfactory.
Reducing Debt: SRPT's debt to equity ratio has increased from 43.9% to 100.5% over the past 5 years.
Debt Coverage: SRPT's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: SRPT earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 05:58 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sarepta Therapeutics, Inc. is covered by 54 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Zhiqiang Shu | Berenberg |